GlobalData on MSN5d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
MM&M2d
Rx Rundown: Moderna, Sanofi, GSK and more
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
pharmaphorum5d
Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab
Drugs selected for clinical trials must show enough potential to be significant improvements over standard care ... for rare autoimmune skin disorder bullous pemphigoid in June.
Monthly Prescribing Reference4d
Dupilumab Gets Priority Review for Bullous Pemphigoid
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
Medscape2d
Dupilumab Under FDA Priority Review for Bullous Pemphigoid
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.